Parkinson’s disease affects more than 10 million people worldwide. Discover its causes, symptoms, and the latest innovations ...

The FDA has approved Capsida Biotherapeutics' investigational new drug (IND) application for CAP-003 to treat Parkinson’s ...

Although our cellular clocks differ dramatically, scientists argue that human aging is one of the highest risk factors for a ...

Aspen Neuroscience, Inc. announced its participation in "Illuminating the Future," the International Society for Stem Cell ...

Discover how Parkinson's disease begins in the gut, not the brain. Learn the early digestive warning signs that appear years ...

Bayer subsidiary BlueRock Therapeutics has dosed the first Parkinson's disease patient in a phase 1 trial of its cell-based therapy DA01, which aims to replenish the neurons lost in people with ...

Ambio will test ibogaine, an experimental, naturally occurring psychedelic, as a therapy for neurodegenerative conditions ...

The article discusses the mental health effects of Parkinson's disease, shedding light on its impact beyond physical motor ...

Bayer subsidiary BlueRock Therapeutics has been granted a fast-track review by the FDA for DA01, its stem cell-based therapy for Parkinson's disease which is currently in early-stage clinical testing.

What if nicotine—which we associate with addiction—actually holds the key to treating depression, ADHD, Alzheimer's, & Parkinson's? Discover the surprising medical revolution.

The“2025 Frost & Sullivan China Entrepreneurs Annual Conference and Forbes China Pioneer Innovators in Industry Developme ...

Tools created in Mayo Clinic's Neurobiology of Parkinson's Disease and Related Disorders aid rapid screening of compound libraries for chemicals targeting oligomeric stage of fibrillization.